Spots Global Cancer Trial Database for lenograstim
Every month we try and update this database with for lenograstim cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | NCT00499018 | Diffuse Large B... IPI≥2 | Rituximab Ciclofosfamide Doxorubicina Vincristina Prednisone Pegfilgrastim Mitoxantrone ARA-C Lenograstim BCNU ARA-C VP-16 ASCT Ciclofosfamide Doxorubicina Vincristina | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy | NCT01085058 | Hodgkin's Disea... Non-Hodgkin Lym... Multiple Myelom... | lenograstim | 18 Years - 70 Years | WiSP Wissenschaftlicher Service Pharma GmbH | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | NCT00379574 | Lymphoma, Large... Lymphoma, B-Cel... | Bortezomib Cyclophosphamid... Doxorubicin Vincristine Prednisolone Lenograstim | 15 Years - 70 Years | Asan Medical Center | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors | NCT00551122 | Brain and Centr... Extragonadal Ge... Ovarian Cancer Testicular Germ... | filgrastim lenograstim pegfilgrastim cisplatin gemcitabine hyd... ifosfamide paclitaxel | 16 Years - 60 Years | University of Southampton | |
| Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors | NCT00551122 | Brain and Centr... Extragonadal Ge... Ovarian Cancer Testicular Germ... | filgrastim lenograstim pegfilgrastim cisplatin gemcitabine hyd... ifosfamide paclitaxel | 16 Years - 60 Years | University of Southampton | |
| Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma | NCT00932217 | G-CSF, Multiple... | filgrastim lenograstim | 18 Years - 70 Years | University of Pisa | |
| Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors | NCT00551122 | Brain and Centr... Extragonadal Ge... Ovarian Cancer Testicular Germ... | filgrastim lenograstim pegfilgrastim cisplatin gemcitabine hyd... ifosfamide paclitaxel | 16 Years - 60 Years | University of Southampton | |
| Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy | NCT01085058 | Hodgkin's Disea... Non-Hodgkin Lym... Multiple Myelom... | lenograstim | 18 Years - 70 Years | WiSP Wissenschaftlicher Service Pharma GmbH | |
| A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) | NCT01907009 | Castrate Resist... | Melphalan Lenograstim | 18 Years - | Barts & The London NHS Trust |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
